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SUMMARY
Human Bartonellosis has an acute phase characterized by fever and hemolytic anemia, and a chronic phase with bacillary 
angiomatosis-like lesions. This cross-sectional pilot study evaluated the immunology patterns using pre- and post-treatment samples 
in patients with Human Bartonellosis. Patients between five and 60 years of age, from endemic areas in Peru, in the acute or chronic 
phases were included. In patients in the acute phase of Bartonellosis a state of immune peripheral tolerance should be established 
for persistence of the infection. Our findings were that elevation of the anti-inflammatory cytokine IL-10 and numeric abnormalities 
of CD4+ and CD8+ T-Lymphocyte counts correlated significantly with an unfavorable immune state. During the chronic phase, the 
elevated levels of IFN-g and IL-4 observed in our series correlated with previous findings of endothelial invasion of B. henselae in 
animal models. 
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INTRODUCTION
Infection with Bartonella species has been associated with Carrion’s 
Disease, Trench Fever, Cat Scratch Disease, bacillary angiomatosis, 
endocarditis, and bacillary peliosis21,22. In Peru, Carrion’s Disease or 
Human Bartonellosis (HB) has been recorded since the times of pre-
Columbian cultures1. The female sandfly of the genus Lutzomyia ssp. is 
the vector of transmission28, and has been mainly reported between 500 
and 3200 meters of elevation21,28. The etiologic agent of HB is Bartonella 
bacilliformis, an aerobic, pleomorphic and monopolar flagellated Gram-
negative bacterium which is surrounded by aggregative fimbriae22,24. 
These bacteria may produce an acute (Oroya Fever) or chronic (Peruvian 
Verruca) infection with different clinical presentations21,22,28.
The acute phase (Oroya Fever) is characterized by fever and severe 
hemolytic anemia with hepatosplenomegaly, jaundice and pallor. The 
mortality rate of the acute phase varies between 1% in hospitalized 
patients and 88% in untreated patients21,28. Asymptomatic carriers 
have been described in endemic areas, with prevalence up to 5% in the 
population21,22,28.
Complications of the acute phase include myocarditis, subacute 
pericarditis, neurobartonellosis, and co-infections with Salmonella sp., 
Toxoplasmosis, Tuberculosis, pneumococcal pneumonia, Pneumocystis 
jiroveci pneumonia, and Staphylococcus aureus sepsis21,22. As explanation, 
as early as 1926, Dr. Weiss in Peru theorized that an immune “anergic” state 
must exist during the HB infection based on clinical observation of severe 
co-infections and a failure in some patients to respond to the tuberculin skin 
test6,10,21,22,29. Non-infectious complications such as congestive heart failure, 
thrombocytopenia, severe anemia, seizures, intracranial hypertension, and 
multi-organ dysfunction have been reported21,22,28.
The chronic phase of Bartonellosis may follow the acute process, 
usually after one or two months2, and is characterized by the development 
of a single or hundreds of verrucas that may histopathologically resemble 
bacillary angiomatosis or Kaposi’s sarcoma21,22,25,28. The verruca is 
characterized by angioblastic hyperplasia, activation of Langerhans 
cells, deposit of IgM, IgA, and complement C3 in endothelial cells, with 
subsequent altered morphology and function6,28,33.
As a pilot study, we measured Th1/Th2 and regulatory cytokines, 
as well as CD4+ and CD8+ T cells in patients in the acute and chronic 
phases of HB, to determine immunological patterns, differences, and 
data for future research.
MATERIALS AND METHODS
Patients and clinical evaluation: For this pilot study, patients were 
enrolled at a reference hospital in Lima-Peru, Hospital Nacional Cayetano 
Heredia, and two hospitals located in endemic areas for HB, Hospital 
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Regional de Huaraz and Hospital de Apoyo de Caraz, in Ancash-Peru 
(Fig. 1).
The patients were selected using the following criteria: aged between 
five and 60 years old, resident of endemic area, and clinical diagnosis of 
B. bacilliformis infection (acute or chronic), according to standard criteria 
of the Peruvian Ministry of Health28 and confirmed by peripheral smear 
and/or blood culture in patients with acute-phase HB. The exclusion 
criteria were: pregnancy or amenorrhea during the previous month, 
use of antibiotics in the previous two weeks7,11, previous use of oral or 
systemic steroids, chemotherapy, cancer, and co-infection with HIV or 
other immunodeficiency. Healthy subjects considered as controls were 
non-pregnant residents from Lima, without previous infection of B. 
bacilliformis, recent illnesses, or previous history of primary or secondary 
immunodeficiency. No controls were considered from the endemic area 
because of the possibility of including asymptomatic patients infected 
with B. bacilliformis21. 
Patients or tutors signed an informed consent, previously approved by 
the Ethics Committee of the Universidad Peruana Cayetano de Heredia 
(ID CIE: 04095). 
Immunohistochemical analysis and cytokines measurement: 
Specimens were collected upon enrollment in the study, at discharge 
from the hospital for those admitted, or during the follow up visit for 
those outpatients. The specimens were collected in 10 mL vacutainer 
tubes with EDTA, and sent to Lima for analysis.
The immunological studies were performed in the Laboratory of 
Immunology of the “Alexander von Humboldt” Institute of Tropical 
Medicine (IMT-AvH), of the Universidad Peruana Cayetano Heredia 
in Lima-Peru. The absolute number of CD4+ and CD8+ T cells were 
measured in peripheral blood using saturating concentrations of 
combinations of anti-CD3-peridinin chlorophyll protein (PerCP), anti-
CD4-fluorescein isothiocyanate (FITC) and anti-CD8-phycoerythrin 
(PE) (Becton Dickinson, Erembodegem, Belgium), according to the 
manufacturer’s instructions. Data were analyzed using the CellQuest 
software (Becton Dickinson, San Diego) in a fluorescence activated cell 
sorter (FACS Calibur) (Becton Dickinson, San Diego).
The levels of IFN-g, TNF-α, IL-4, IL-10, and TGF-b in the patient’s 
plasma were evaluated using commercial Kits (BD OptEIATM ELISA 
kits-®). The concentrations of cytokines (in pg/mL) and TGF-b (in 
ng/mL) were measured using an ELISA reader (Biorad-®).
Data analysis: Because most of the variables showed non-normal 
distribution (Table 1 and Table 2), the Cytokines and CD4+/CD8+ T-cells 
counts from acute and chronic patients, both before and after treatment, 
were compared using the non-parametric Wilcoxon test. Differences 
among pre-treatment, post-treatment, and control samples were evaluated 
using the non-parametric Kruskal-Wallis test. We considered every 
difference for which the probability of similarity was less than 0.05 
(p < 0.05) as being significant.
RESULTS
General Data: Patients were included in this study between October 
2004 and June 2006. Nine healthy subjects were included as controls. 
Thirty patients in the acute phase were initially included in the study. 
Subsequently, three of them were excluded for pregnancy, and fourteen 
others whose infection was not confirmed (negative peripheral smear and 
blood culture). Finally, 13 patients were included in the analysis. The 
mean age of the 13 patients with acute-phase HB was 26.4 years (range: 
5 - 49 years old), with a mean duration of illness of 16.3 days (range: 2 - 
30 days). Because hemolyzed samples and samples that arrived after 12 
hours from the endemic area were not analyzed, only eight post-treatment 
blood samples were included in the study. The descriptive statistics are 
shown in Table 1.
Forty -two patients were initially included with diagnosis of chronic-
Fig. 1 - Map of endemic area in Peru
Table 1
Descriptive statistics of immunology pattern in patients with acute-phase 
human Bartonellosis
A. Pre Treatment
n minimum maximum median
WBC 09 5300 10250 7054.77*
CD4+ 13 81 1279 675.00 
CD8+ 13 75 3285 455.00 
CD4/CD8 13 0.36 3.48 1.65 
IFN-g 11 13.13 1248.75 50.63 
TNF-α 12 0.00 3.61 1.39*
IL-4 12 0.00 22.33 3.85 
IL-10 12 7.20 343.46 49.30 
TGF-b 09 12.25 27.70 15.45
B. Post Treatment
n minimum maximum median 
WBC 06 5500 9800 7641.67*
CD4+ 06 261 1871 929.33*
CD8+ 06 245 3765 1230.00
CD4/CD8 06 0.27 1.82 0.88
IFN-g 06 6.88 50.52 24.15*
TNF-α 06 0.00 30.25 1.95
IL-4 05 0.00 4.40 2.16
IL-10 06 2.81 107.44 14.51
TGF-b 00
* mean
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phase HB. However, 21 patients were excluded from the analysis (twenty 
because of previous use of antibiotics and one for an age outside the 
inclusion criterion). Post-treatment samples were obtained from eleven 
patients. The mean age of the patients in the chronic phase was 27.2 
years (range: 9 - 51 years old), and the mean duration of illness was 
42 days (range: 14 - 120 days). The descriptive statistics are shown in 
Table 2.
Quantitative analysis of Cytokines in plasma: The differences 
in pre-treatment values obtained in the acute phase patients at time 
of enrollment and those obtained in the controls were not statistically 
significant for white blood cells (WBC) count, IFN-g, TNF-α level, 
IL-4, and TGF-b, except for IL-10 (p < 0.05). Similar findings were 
observed in the post-treatment samples compared with controls, with 
p < 0.05 for IL-10.
The differences in pre-treatment samples from acute-phase (Table 
1) and chronic-phase (Table 2) patients were not statistically significant 
for WBC count, TNF-α level, TGF-b, and IL-4, except for IFN-g (p = 
0.018) and IL-10 (p = 0.011). The post-treatment samples from acute-
phase (Table 1) and chronic-phase (Table 2) patients were not statistically 
significantly different for WBC count, TNF-α level, IFN-g, TGF-b, and 
IL-4, except for IL-10 (p = 0.048).
The pre-treatment samples analysis from acute phase cases and 
controls were significantly different only for IL-10 (p = 0.003). The 
differences in post-treatment samples between the acute phase cases and 
controls were significant only for IL-10 (p = 0.007) (Fig. 2).
Four of the 13 cases of acute-phase HB were considered complicated, 
due to co-infection with Epstein-Barr virus and CMV, a case of pericarditis 
(with 78% of parasitemia), a case of neuro-bartonellosis (with 98% of 
parasitemia), and a death. The patient who died showed the highest 
level of IL-10 in the series (343.46 pg/mL). No numeric abnormalities 
in T-Lymphocyte count were seen in these patients (Table 1). 
The difference between pre-treatment samples from chronic-phase 
patients and samples from controls were not statistically significant 
Table 2
Descriptive statistics of immunology pattern in patients with chronic-phase 
human Bartonellosis
A. Pre Treatment
n minimum maximum median
WBC 15 2200 10700 5953.33*
CD4+ 18 188 1952 813.00
CD8+ 18 181 1548 676.28*
CD4/CD8 18 0.21 3.28 1.51*
IFN-g 21 0.00 790.67 17.50
TNF-α 21 0.00 6.22 0.32
IL-4 20 0.00 42.65 1.65
IL-10 21 0.60 105.24 14.36
TGF-b 20 11.60 117.55 19.55
B. Post Treatment
n minimum maximum median
WBC 04 4700 7100 5100.00
CD4+ 05 791 1175 880.00
CD8+ 05 574 997 744.00
CD4/CD8 05 0.82 1.47 1.38
IFN-g 10 0.00 134.00 9.78
TNF-α 10 0.00 2.99 0.88*
IL-4 11 0.00 135.00 1.47
IL-10 11 0.00 18.90 3.20
TGF-b 00
* mean
Fig. 2 - Cytokine’ counts in patients with human Bartonellosis.
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for WBC count, TNF-α level, and IL-10, except for p-value of IFN-g 
(p = 0.07) and IL-4 (p = 0.015). The post-treatment samples from the 
chronic-phase cases and controls were significantly different only in 
IFN-g (p = 0.010).
Quantitative analysis of T-Lymphocyte cell count in plasma: 
During the acute phase, the lowest CD4+ T-lymphocyte count was 81. 
Four patients in total had a CD4+ T-lymphocytes count below 150 in the 
acute-phase HB sample (Table1). One patient had a CD8+ T-lymphocyte 
count of 75, with a normal count of CD4+ (261 cell/µL) and the highest 
count of IFN-g (1248.75 pg/mL). No numeric abnormalities were noted 
in patients with chronic-phase HB (Table 2). Pre-treatment samples from 
acute cases and from the controls showed no statistical difference in 
either CD4+ or CD8+ T-lymphocyte count. The post-treatment samples 
from chronic cases were significantly higher than the controls in CD8+ 
count with p = 0.042 (Fig. 3). 
DISCUSSION 
During the previous several decades, studies have focused on the 
effects of B. bacilliformis on the host. Based on studies performed during 
the 1980’s and 1990’s it is accepted that during the acute-phase of the 
disease the humoral response is activated6,28. The antigen-presenting 
cells are activated, as is the complement cascade (including the classic 
and alternative pathway), due to antigenic proteins exposed on red blood 
cells, as well as increased IgM levels3,6,24,29. Clinically focused studies 
have shown that the acute phase of HB may be manifested in the host 
with a diversity of severities, from asymptomatic to acute life-threatening 
hemolytic anemia with multiple complications6,21,22,28 characteristics 
of patients with IRIS. A similar variety in presentations and severities 
due to Bartonella henselae has been shown to have a close correlation 
with the host’s immune status30. Interestingly, HENRIQUEZ et al.12 
described a case of persistent B. bacilliformis bacteremia in a situation 
of altered immunological state. It has been reported that the intensity of 
the inflammatory response in any case, depends on previous exposure to 
B. bacilliformis22 and probably on genetic predisposition32.
Recently the significance of Th1-cell derived cytokines in resistance 
to bacterial invasion has been seen to play important roles during B. 
henselae infection and in the induction of angiogenesis27,30, a process that 
may explain the effective phagocytic function in the immunocompetent 
individual is responsible for the localized, non-systemic expression of 
Cat Scratch Disease14,30. Due to limited research in HB in this area, we 
looked for similarities, but no clear Th1- or Th2- cell derived cytokines 
were found. However, similar to an induction of IFN-g and IL-12 (not 
measured in our study) observed with B. henselae stimulation in rodents26, 
our series of patients showed a significant initial elevation of IFN-g 
(Fig. 2) and a non-significant elevation of TNF-α (Table 1) as part of 
the inflammatory process that also can be seen in other gram-negative 
infections4,19. 
Although the immunopathology that develops during HB is unclear, 
some theoretical models have been proposed6,32. A few important findings 
described recently implicated the role of Toll-like receptors (TLRs). 
TLRs are part of an important family of innate immune receptors that 
recognize pathogen-associated molecular patterns, but is not activated by 
flagellin molecules of B. bacilliformis2,31. Thus the bacteria avoid being 
recognized by epithelial cells and dendritic cells, and thus do not activate 
the pro-inflammatory response14. The bacterias are therefore able to bind 
and to invade red blood cells6,21,28. In addition, the lack of activation of 
dendritic cells will prevent the reversal of Treg cells in anergic states15,34. 
Thus, preventing the activation of dendritic cells, B. bacilliformis may 
establish and maintain an immune peripheral tolerance in the host6,32. 
Finally, this impairment in the cellular immunity favors the reactivation 
of intracellular infections such as tuberculosis and Toxoplasmosis, which 
are commonly reported in the endemic areas21,22.
The phenomenon of peripheral tolerance may be enhanced by 
cytokines such as IL-10, which by disarming innate as well as adaptive 
responses creates conditions for microbe persistence and chronic Fig. 3 - T-lymphocyte cells count in patients with human Bartonellosis.
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infectious disease23. Elevation of IL-10 is due mainly to CD43+CD4+ 
T-cells, which are important in the equilibrium between Th1 and Th2 
responses18. Th2 cytokines, including IL-10, inhibit the secretion of 
pro-inflammatory cytokines19,20. Given these observations, our finding 
of statistically significant elevated levels of IL-10 in patients with 
acute-phase HB (Fig. 2) may not be surprising. Unfortunately, we did 
not find significant differences in concentration of pre-treatment TGF-
beta, which is also involved in immune suppression and angiogenesis9,35. 
These observations suggest further studies, including the measurement 
of cytokines in directly stimulated Lymphocytes with B. bacilliformis 
antigens which will avoid the possibility of erroneous attribution of 
cytokine levels due to other multiple factors other than the bacteria 
of interest. In addition, because of its short half-life in plasma5,17, it is 
important to measure IL-10 immediately after sample collection.
Descriptions of anergy and clinical complications seen only in 
immunocompromised patients, as in AIDS, were the reasons why 
T-Lymphocytes were counted in early studies. PATRUCCO29, was the 
first to report patients with a decreased number of CD4+ T-Lymphocytes, 
but also, and more importantly, deficiencies in their function. Among 
our patients, significantly low counts of CD4+ and CD8+ T-Lymphocytes 
were found, that are resolved following appropriate treatment (Tables 1 
and 2). Cytotoxic T-Lymphocytes may be required to clear bacteria from 
sequestered sites such as the vascular endothelial tissue and lymphoid 
organs12,14. This transitory numeric abnormality in T-cell count may also 
explain co-infections and other complications previously described21,22,28. 
Further studies with a more adequate sample size may confirm this 
finding, as well as the functional compromise in the cellular immune 
response described initially by PATRUCCO29. 
The eruptive phase of HB is characterized by endothelial compromise, 
by mechanisms that are still unclear, but it is known that B. bacilliformis, 
B. henselae, and B. quintana can produce similar angiogenic factors16,21,22 
and that B. bacilliformis is captured by endothelial cells in a process that 
involves the GTPase Rho protein3,8. Interestingly, the vascular proliferation 
as seen in the chronic-phase of HB resembles the morphologic findings 
in patients with AIDS, Kaposi’s sarcoma, and Bacillary Angiomatosis, 
all of which exist only in immune-deficient states6,10. 
In our group of patients in the chronic phase we found significantly 
elevated levels of IFN-g and IL-4 (Fig. 2 and Table 2). These finding 
may be explained by the active role of the humoral immune reaction 
in limiting the bacterial presence to the vascular epithelial tissue and 
the role of IFN-g in the enhancing phagocytic activity14. These findings 
also resemble observations in an animal model with elevated levels of 
IFNg- and IL-4 after a systemic inoculation with B. henselae antigen13, 14.
In summary, the varied severity of clinical presentation by patients 
with acute-phase HB should be considered to be related to the patient’s 
immune status, with a state of immune peripheral tolerance needed 
to establish persistent infection2,14,15,34. Our findings of statistically 
significant elevation of the anti-inflammatory cytokine IL-10 and 
numeric abnormalities in the CD4+ and CD8+ T-Lymphocyte counts 
correlates with an immune state unfavorable for infection clearance. 
The chronic phase of HB resembles histologically diseases prevalent in 
immune-deficient conditions, such as Kaposi’s sarcoma, and Bacillary 
Angiomatosis6,10,16. However, there is no clear explanation for this 
resemblance. Finally, elevated levels of IFN-g and IL-4 observed in our 
work correlated positively with previous findings in animal models of 
B. henselae endothelial invasion26. 
RESUMEN
Citoquinas y recuento de Linfocitos T en pacientes en fase aguda 
y crónica de infección por Bartonella bacilliformis, en una área 
endémica del Perú: estudio piloto
La Bartonelosis Humana, tiene una fase aguda caracterizada por 
fiebre y anemia hemolítica, así como una fase crónica con lesiones 
semejantes a angiomatosis bacilar. En un estudio transversal piloto los 
patrones inmunológicos en pacientes con Bartonelosis Humana fueron 
estudiados mediante muestras pre y post tratamiento. Pacientes entre 5 
y 60 años en fase aguda y crónica fueron incluidos en área endémica 
del Perú. En aquellos pacientes con fase aguda, una fase de tolerancia 
inmunológica periférica es necesaria para la persistencia de la infección. 
Los hallazgos de significativa elevación de citoquina anti-inflamatoria 
(IL-10) y anormalidades numéricas en el recuentos de Linfocitos T CD4+ 
y CD8+ correlacionan con un estado inmune que favorece la infección. 
Durante la fase crónica, elevados niveles de INF-g y IL-4 observados 
en la serie de pacientes correlacionan con previos hallazgos en modelos 
animales que favorecen la invasión del endotelio por B. henselae. 
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